Use of antirheumatic medication
| 1994 | 1996 | 2001 | 2004 | 2009 | |
|---|---|---|---|---|---|
| (n=931) | (n=1025) | (n=829) | (n=914) | (n=986) | |
| Glucocorticosteroids | |||||
| Overall | 379 (40.7) | 436 (42.5) | 354 (42.7) | 379 (41.5) | 341 (34.6) |
| Women | 293 (40.9) | 340 (42.7) | 267 (41.8) | 301 (41.7) | 265 (35.0) |
| Men | 86 (40.0) | 96 (42.1) | 87 (45.8) | 78 (40.4) | 76 (33.3) |
| sDMARD | |||||
| Overall | 339 (36.4) | 405 (39.5) | 401 (48.4) | 495 (54.2) | 587 (59.5) |
| Women | 266 (37.2) | 316 (39.6) | 312 (48.8) | 391 (54.2) | 448 (59.1) |
| Men | 73 (34.0) | 89 (39.0) | 89 (46.8) | 104 (53.9) | 139 (61.0) |
| bDMARD | |||||
| Overall | NA | NA | 27 (3.3) | 108 (11.8) | 202 (20.5) |
| Women | NA | NA | 24 (3.8) | 88 (12.2) | 157 (20.7) |
| Men | NA | NA | 3 (1.6) | 20 (10.4) | 45 (19.7) |
All values: n (%). p Values for difference between men and women at all time points were non-significant (p>0.05).
bDMARD, biological disease modifying antirheumatic drug; sDMARD, synthetic disease modifying antirheumatic drug; NA, not applicable.